Inhibrx (INBX) | Stock Overview & Key Data
Inhibrx Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $155.29 on April 22, 2026
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Inhibrx
INBX
|
1.75B Small-cap | -12.29% | -26.75% | 20.94% | 13.95% | 24.89% | 672.16% | 322.80% | 375.58% | 409.10% | 409.10% | 409.10% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.49% | -1.11% | -12.54% | -1.86% | -5.98% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -5.03% | -15.02% | -23.79% | -18.77% | -22.36% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Recursion
RXRX
|
1.85B Small-cap | 21.89% | 2.84% | -0.28% | -16.20% | -13.81% | -14.11% | -56.38% | -87.80% | -88.53% | -88.53% | -88.53% |
|
Capricor
CAPR
|
2.04B Mid-cap | -6.88% | -18.39% | 1.79% | 329.87% | -3.43% | 202.93% | 558.46% | 676.17% | -7.24% | -90.64% | -97.72% |
|
Zymeworks
ZYME
|
1.96B Small-cap | -5.08% | -9.97% | 3.43% | -3.94% | -9.43% | 119.86% | 189.85% | -20.78% | 93.31% | 93.31% | 93.31% |
Ownership & Short Interest
Calculate Your Inhibrx Investment Returns
Long-Term Investment Performance Analysis
Inhibrx stock price in Aug 2020 was $20.43, A $1,000.00 lump sum investment in Inhibrx made 5 years ago would be worth approximately $4,660.79 today, representing a exceptional return of 366.08%. This translates to an annualized return (CAGR) of 30.43%.
5 Years 9 Months Investment Scenario (Aug 2020 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is INBX's 52-week high and low?
- In the last 52 weeks, Inhibrx reached a high of $155.29 (on April 22, 2026) and a low of $12.80 (on June 5, 2025).
- What is the market cap and P/E ratio for INBX?
- Curious about Inhibrx's size and valuation? Its market capitalization stands at 1.75B. When it comes to valuation, the P/E ratio (trailing twelve months) is 0.20, and the forward P/E (looking ahead) is -42.99.
- Does INBX pay dividends? If so, what's the yield?
- As for dividends, Inhibrx isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Inhibrx's main competitors or similar companies to consider before investing?
When looking at Inhibrx, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Recursion
RXRX1.85B Healthcare Biotechnology -14.11% -56.38% Capricor
CAPR2.04B Healthcare Biotechnology 202.93% 558.46% Zymeworks
ZYME1.96B Healthcare Biotechnology 119.86% 189.85% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Inhibrx Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Inhibrx's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -197.85%, the Debt to Equity ratio from the most recent quarter is 1,338.82, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for INBX?
- Looking at Inhibrx's growth, its revenue over the trailing twelve months (TTM) was $1M. Compared to the same quarter last year (YoY), quarterly revenue grew by -100.00%, and quarterly earnings saw a YoY growth of -100.00%.
- How much of INBX stock is held by insiders and institutions?
- Wondering who owns Inhibrx stock? Company insiders (like executives and directors) hold about 26.95% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 81.73%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.